Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Do Accelerated Approval Pathways Mean Earlier Patient Access?

Accelerated access mechanisms that aim to get medicines to the market more quickly do not necessarily mean earlier access for patients, according to interim findings from a London School of Economics study.

Europe Drug Review Drug Approval Standards

Right-To-Try Legislation Must Change Language To Narrow Spectrum Of Patients, Gottlieb Says

US FDA commissioner tells House hearing that the Senate's legislation in its current form could undermine the intent of addressing terminally ill patients.

FDA Research & Development Legislation

Pfizer Skeptical About Value-Based Contracting In Current Environment

'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'

Pricing Strategies Market Access Commercial

Advertisement
UsernamePublicRestriction

Register

Advertisement